Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd.

University of Dundee

Jeremy Besnard

Hidefumi Yoshinaga

Andrew Simon Bell

Yoshinori Aihara

Yohei Ikuma

Satoshi Adachi

Junya Ikeda

Harunobu Mitsunuma

Hiro Uemachi

Tomomi Ohno

Ian Gilbert

Gian Filippo Ruda

Yuki Fujii

Andrew Lee Hopkins

Masayuki Sakuma

Keren Abecassis

The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.

Substituted pyrazoles showing serotonin 5-HT receptor activity

The present invention relates to a pyridine derivative of formula (1) wherein Ris optionally-substituted Calkyl, optionally-substituted Ccycloalkyl, or optionally-substituted 5- to 10-membered saturated or partially-unsaturated heterocyclyl; Ris halogen atom, cyano, Calkyl which may be optionally substituted with 1 to 3 the same or different halogen atoms, Calkoxy which may be optionally substituted with 1 to 3 the same or different halogen atoms, or amino which may be optionally substituted with 1 to 2 the same or different Calkyl; and the bind with broken line is single or double bond, or a pharmaceutically acceptable salt thereof, which is useful as a medicament for treating symptoms in anxiety-related disorder.

2,6-disubstituted pyridine derivative

Substituted lactams showing serotonin 5-HT receptor activity

The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HTreceptors and serotonin 5-HTreceptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; Rthrough R, Rthrough R, and Rthrough Rare a hydrogen atom and the like; Ris alkyl and the like; and Q is a specific bicyclic group.)

Aliphatic acid amide derivative

The present invention relates to a pyridine derivative of formula (1) wherein Ris optionally-substituted Calkyl, optionally-substituted Ccycloalkyl, or optionally-substituted 5- to 10-membered saturated or partially-unsaturated heterocyclyl; Ris halogen atom, cyano, Calkyl which may be optionally substituted with 1 to 3 the same or different halogen atoms, Calkoxy which may be optionally substituted with 1 to 3 the same or different halogen atoms, or amino which may be optionally substituted with 1 to 2 the same or different Calkyl; and the bind with broken line is single or double bond, or a pharmaceutically acceptable salt thereof, which is useful as a medicament for treating symptoms in anxiety-related disorder. 

Condensed lactam derivative

The invention relates to morpholino-derivatives according to Formula (I) or stereoisomers or pharmaceutically acceptable salts or solvate thereof, wherein R, R, R, R, R, R, R, R, R, m and n are as defined in the specification. The compounds are antagonists, reverse agonists or agonists of G-protein coupled receptors, such as dopamine D4 and 5HT1a. The inventions also relates to pharmaceutical compositions comprising the compounds and methods involving the compounds and compositions. The compounds and compositions of the invention may in particular be used in the treatment of diseases and disorders, such as neurological and neurodegenerative diseases; or as lead compounds for the design and selection of further therapeutic compounds. 

Morpholino compounds, uses and methods

Growing community of inventors

Dundee, United Kingdom

Jeremy Besnard